H.I.G. Realty Partners Expands European Team with the Addition of Jérome Fouillé and Jenny Hammarlund as Managing Directors
H.I.G. Capital (“H.I.G.”), a leading global alternative asset management firm with over $30 billion of equity capital under management, is pleased to announce that Jérome Fouillé and Jenny Hammarlund have joined the firm’s real estate team as Managing Directors. Jérome and Jenny together bring over 35 years of experience originating, structuring and investing in real estate equity and debt. They are based in H.I.G.'s London office.
Prior to H.I.G., Jérome worked for GIC as Managing Director and Head of Tactical Opportunities where he was responsible for investments in Europe targeting Core+ to Value Add transactions across a wide range of asset classes. Prior to this, he was a Senior Vice President at Colony Capital and at Heitman. Jérome holds an M.B.A. from The London Business School.
Prior to H.I.G., Jenny was a Director in the real estate team at KKR, where she focused on sourcing and executing real estate investments across Europe. Prior to this, Ms. Hammarlund was a Director at Värde Partners in London and a Vice President at Lehman Brothers Real Estate Partners in New York. Jenny holds an M.B.A. from Columbia Business School.
Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: "I am delighted to welcome Jenny and Jérome to the firm. They are very experienced and successful real estate investors who significantly augment the expertise and capabilities of our team. I am confident they will play an instrumental role in H.I.G. Realty’s growth in Europe."
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with over $30 billion of equity capital under management.* Based in Miami, and with European offices in London, Hamburg, Madrid, Milan, Paris, and U.S. and Latin American offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, Stamford, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach:
1. H.I.G.’s equity funds invest in growth investments, management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005520/en/
Contact information
Riccardo Dallolio
Managing Director
rdallolio@higrealty.com
H.I.G.
Europe Realty Partners
www.higrealty.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 15:00:00 EEST | Press release
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,” said Dr. A
Pure Lithium Founder & CEO Emilie Bodoin Recognized for Trailblazing Woman of the Year at 2025 Volta Foundation Awards at 17 th Annual Fastmarkets Lithium Supply and Battery Raw Materials Conference27.6.2025 13:00:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that its Founder, Chairman & CEO, Emilie Bodoin received special recognition for Trailblazing Woman of the Year Award Sponsored by ExxonMobil at the 2025 Fastmarkets Volta Awards Ceremony, in Las Vegas, Nevada on June 24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627170164/en/ This award celebrates an exceptional female leader who has demonstrated outstanding leadership, vision, and impact within her industry. It recognizes achievements in driving innovation, fostering diversity, and inspiring others while making significant contributions to her organization. “I am truly honored to receive special recognition for this award. One of the best things about my role is the opportunity to lead by example and encourage and inspire women and girls who may not yet recognize their potential. To all of m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom